Author: Julius

The 5th Antibody Symposium held on 5th & 6th March 2018 was jointly organised by Chugai Pharmabody Research Pte Ltd, Denka Life Innovation Research Pte Ltd (DLIR), Nanyang Technological University, p53Lab, and A*STAR. The theme was “Current progress in antibodies-therapeutics & diagnostics”.

The Festival aimed to make science and technology more accessible to the masses and to bring together youths, young working professionals, entrepreneurs and researchers in a creative intermix of science, technology, media and enterprise.

This year’s theme was “Pioneering an Innovative Future”; it embodied how technologies in one-north are playing a key role in value creation, and demonstrated to the public that the future is bright and that they can and will be a part of it.

CPR and SigN co-presented “A therapeutic antibody for dengue” in the “Future Health” sector.

The annual BioPharma Asia Convention is the leading event for Asia’s biopharma industry. This year marks the 7th, and it was held in Suntec Singapore International Convention & Exhibition Centre from 10th Mar to 13th Mar. The purpose of this convention is to bring together decision makers and influentials from the pharma and biotech industries, academia, CROs as well as CMOs, as it delivers an unparalleled opportunity to convene, network and deliberate. CPR was invited as a speaker to present our latest antibody production platform. Approaches to overcome the bottlenecks of antibody production in early-stage R&D were discussed.

CPR is proud to join Biopolis in its 10th anniversary celebrations by taking up a booth to showcase our company activities at the Biopolis Carnival. At the booth, we had the opportunity to converse with over 800 visitors as we presented them with our antibody-shaped balloons. Since Chugai’s first satellite lab (PharmaLogicals Research) commenced its operations here in Singapore in 2002, and later, CPR in 2012, it has been playing a key role in the area of research of pharmaceutical business by utilising Singapore’s Biomedical Sciences environment to its advantage. It is a great honour for us to be marked in Biopolis’s glorious history and we further strive to achieve our goals to create innovative antibody drugs that can address unmet medical needs.

A presentation to explain CPR’s proprietary antibody engineering technology, Recycling & Sweeping antibody technology, was given at Drug Discovery World Asia 2013 by CPR’s Research Head Dr Junichi Nezu. The symposium was held in conjunction with the 6th Annual BioPharma Asia Convention 2013 from 19-20 March 2013 at Resorts World Convention Center, Sentosa,  Singapore. Biopharma Asia Convention 2013 is known as Asia’s largest biopharmaceutical industry gathering, focusing on innovation and strategies for pharmas, biotechs and the R&D community.

The 4th antibody symposium, co-organised by p53 Laboratory, A*STAR Biomedical Sciences Institutes and CPR, was held at Matrix, Biopolis with around 300 audiences. The symposium commenced with an opening address from Mr. Osamu Nagayama, Chairman and CEO of Chugai Pharmaceutical, followed by keynote lectures from Dr. Mark Davis, Stanford University and Prof. Tomohiro Kurosaki, Osaka University IFReC. Dr. Nezu, CPR Research Head, also showed the successful development of bispecific antibody project. CPR is honoured to help provide scientists in Biopolis with cutting-edge antibody research and encourage interaction among government, academia and industry.

The 3rd antibody symposium, co-organised by p53 Laboratory, ASTAR Biomedical Sciences Institutes and Chugai Pharmabody Research, was held in Biopolis, Singapore. The symposium serves to provide a platform for scientists to share cutting-edge antibody researches conducted within ASTAR, the universities and industries in Biopolis. At the opening address, guest of honour, Mr. Lim Chuan Poh, Chairman of A*STAR, expressed his appreciation to Chugai, which had started its research operations in Singapore since 2002. The symposium commenced with a keynote lecture from Dr. Arnold Levine, CPR Director and Emeritus Professor, Institute for Advanced Study. This was an opportunity for five scientists from CPR to introduce their effective antibody drug discovery processes.

The 2nd antibody symposium, co-organised by p53 Laboratory, ASTAR Biomedical Sciences Institutes and Chugai Pharmabody Research, was held in Biopolis, Singapore. At the symposium, a total of 11 scientists presented updates in innovative antibody research that have since been conducted in ASTAR, the academia and the pharma industry to foster greater interaction. Following the brief overview of antibody drug discovery in Chugai and CPR by Dr. Nezu, Research Head of CPR, 4 scientists from Chugai and CPR had the privilege to introduce their innovative antibody technologies. They also took the opportunity to outline several research projects which Chugai and CPR are currently developing.

The antibody symposium co-organised by p53 Laboratory, ASTAR Biomedical Research Institutes and Chugai Pharmabody Research, was held among the scientists who are working in Biopolis, Singapore. Over the 200 participants enjoyed learning about the cutting-edge antibody research in ASTAR, the university and the industry. Chugai’ s innovative antibody technologies, such as recycling and sweeping antibody technology and bispecific antibody which was published online in Nature Medicine October edition, and CPR’ s research function and activities were shown at the symposium.